GH insider ownership: who sold, why, and what they still hold

What stands out

Nine insiders sold $84.6M with no disclosed plan: Helmy Eltoukhy ($22.0M), Chris Freeman ($16.9M) and AmirAli Talasaz ($10.5M), plus 6 more. The filings don't state a reason.Helmy Eltoukhy: largest such sale, Dec 15, 2025 · Chris Freeman: largest such sale, Aug 10, 2026 · AmirAli Talasaz: largest such sale, Dec 8, 2025

Kumud Kalia bought 600 shares for $78K, first on Jun 15, 2026. These are the first by current officers or directors since Mar 18, 2024.Purchase, Jun 15, 2026

A share of stake is shown for 0 of the 15 officers and directors who sold. 18 are left out

Left out: AmirAli Talasaz, Helmy Eltoukhy, Darya Chudova, Chris Freeman, John Saia, Michael Bell, Craig Eagle, Terilyn Monroe, Kumud Kalia, Vijaya Gadde, Steve Krognes, Myrtle Potter, Meghan Joyce, Ian Clark, Musa Tariq, Medina Hidalgo, Roberto Mignone and Alex Azar II (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

AmirAli Talasaz

Co-Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$77.9M87% planned 13% no plan disclosed

Helmy Eltoukhy

Co-Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$22.0MNo plan disclosed

Chris Freeman

Chief Commercial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$16.9MNo plan disclosed

Terilyn Monroe

Chief People Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$15.9M52% planned 48% no plan disclosed

Michael Bell

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$8.8MNo plan disclosed

All 15 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Oct 1, 20268 executives had 54K shares ($9.5M) withheld by the company for taxes (not a market sale). 107K shares came in from vesting or option exercises the same day, so their combined holdings rose by 53K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
AmirAli Talasaz Co-Chief Executive Officer, Director	17,087	$174.75	n/a	n/a	Oct 1, 2026	Oct 2, 2026
Helmy Eltoukhy Co-Chief Executive Officer, Director	17,087	$174.75	n/a	n/a	Oct 1, 2026	Oct 2, 2026
Darya Chudova Chief Technology Officer	4,320	$174.75	n/a	n/a	Oct 1, 2026	Oct 2, 2026
Michael Bell Chief Financial Officer	3,914	$174.75	n/a	n/a	Oct 1, 2026	Oct 2, 2026
John Saia Chief Legal Officer	3,706	$174.75	n/a	n/a	Oct 1, 2026	Oct 2, 2026
Chris Freeman Chief Commercial Officer	3,143	$174.75	n/a	n/a	Oct 1, 2026	Oct 2, 2026
Kumud Kalia Chief Information Officer	3,067	$174.75	n/a	n/a	Oct 1, 2026	Oct 2, 2026
Terilyn Monroe Chief People Officer	2,098	$174.75	n/a	n/a	Oct 1, 2026	Oct 2, 2026

Sep 30, 20262 executives had 2.9K shares ($509K) withheld by the company for taxes (not a market sale). 5.6K shares came in from vesting or option exercises the same day, so their combined holdings rose by 2.8K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
AmirAli Talasaz Co-Chief Executive Officer, Director	1,428	$178.36	n/a	n/a	Sep 30, 2026	Oct 2, 2026
Helmy Eltoukhy Co-Chief Executive Officer, Director	1,428	$178.36	n/a	n/a	Sep 30, 2026	Oct 2, 2026

Sep 16, 2026Steve Krognes sold 6.7K shares ($1.2M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Steve Krognes Director	6,674	$175.74	n/a	n/a	Sep 16, 2026	Sep 17, 2026

Sep 16, 20262 directors sold 942 shares ($165K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Alex Azar II Director	826	$175.00	n/a	n/a	Sep 16, 2026	Sep 17, 2026
Musa Tariq Director	116	$175.00	n/a	n/a	Sep 16, 2026	Sep 17, 2026

Sep 15, 2026Darya Chudova sold 7.7K shares ($1.4M) with no plan disclosed.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Darya Chudova Chief Technology Officer	7,738	$178.00	n/a	n/a	Sep 15, 2026	Sep 17, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

AmirAli Talasaz sold $6.3M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Guardant Health, Inc. CEO selling stock?

Yes. AmirAli Talasaz sold 620K shares ($77.9M) in the past 12 months, 87% of it under a trading plan disclosed in the filings.

Why are Guardant Health, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 48% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 52% had no disclosed plan. A trading plan schedules sales in advance.

Are any Guardant Health, Inc. insiders buying?

Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold15 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
AmirAli Talasaz Co-Chief Executive Officer, Director	$77.9M 620K shares	Not confirmed share of stake is being verified. Why	87% under a disclosed plan 13% no plan disclosed
Helmy Eltoukhy Co-Chief Executive Officer, Director	$22.0M 191K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Chris Freeman Chief Commercial Officer	$16.9M 119K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Terilyn Monroe Chief People Officer	$15.9M 124K shares	Not confirmed share of stake is being verified. Why	52% under a disclosed plan 48% no plan disclosed
Michael Bell Chief Financial Officer	$8.8M 85K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Ian Clark Director	$6.1M 50K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Kumud Kalia Chief Information Officer	$5.9M 56K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Darya Chudova Chief Technology Officer	$4.4M 36K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
John Saia Chief Legal Officer	$4.2M 39K shares	Not confirmed share of stake is being verified. Why	80% under a disclosed plan 20% no plan disclosed
Steve Krognes Director	$2.4M 16K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Meghan Joyce Director	$1.3M 10K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Medina Hidalgo Director	$936K 8K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Musa Tariq Director	$411K 3.3K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Myrtle Potter Director	$206K 1.6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Alex Azar II Director	$145K 826 shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Sold by a charitable foundation the insider reports: Shares held by the Talasaz Family Foundation, reported by AmirAli Talasaz (sold $6.3M); Shares held by The Eltoukhy Foundation, reported by Helmy Eltoukhy. A foundation's shares are not the insider's own stake, so they are left out of the figures above.

The full ownership picture0 of 18 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

AmirAli Talasaz

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for AmirAli Talasaz are complete.

Co-Chief Executive Officer, Director

n/a

−620K

n/a

Vesting, gifts, unvested awards and holding lines for AmirAli Talasaz

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for AmirAli Talasaz are complete; balances and unit counts will be added when the check is finished.

−75Kgifted (net of own trusts)

−102Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
28,997	$4.18	Jul 13, 2027	$5.0M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Helmy Eltoukhy

Co-Chief Executive Officer, Director

n/a

−191K

n/a

Vesting, gifts, unvested awards and holding lines for Helmy Eltoukhy

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Helmy Eltoukhy are complete; balances and unit counts will be added when the check is finished.

−65Kgifted (net of own trusts)

−102Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
511,612	$4.18	Jul 13, 2022	$88.7M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Darya Chudova

Chief Technology Officer

n/a

−36K

n/a

Vesting, gifts, unvested awards and holding lines for Darya Chudova

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Darya Chudova are complete; balances and unit counts will be added when the check is finished.

−3Kgifted (net of own trusts)

−38Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,356	$8.80	Aug 22, 2028	$397K
29,861	$28.37	Dec 13, 2033	$4.5M
59,534	$28.61	Nov 8, 2034	$8.9M
30,453	$43.10	Mar 12, 2035	$4.1M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Chris Freeman

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Chris Freeman are complete.

Chief Commercial Officer

n/a

−119K

n/a

Vesting, gifts, unvested awards and holding lines for Chris Freeman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Chris Freeman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−30Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,620	$110.49	Aug 2, 2031	$242K
701	$32.86	Jun 9, 2033	$101K
1,668	$28.37	Dec 13, 2033	$249K
45,246	$28.61	Nov 8, 2034	$6.7M
23,145	$43.10	Mar 12, 2035	$3.1M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

John Saia

Chief Legal Officer

n/a

−39K

n/a

Vesting, gifts, unvested awards and holding lines for John Saia

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Saia are complete; balances and unit counts will be added when the check is finished.

−800gifted (net of own trusts)

−33Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,861	$28.37	Dec 13, 2033	$4.5M
52,389	$28.61	Nov 8, 2034	$7.8M
26,799	$43.10	Mar 12, 2035	$3.6M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Michael Bell

Chief Financial Officer

n/a

−85K

n/a

Vesting, gifts, unvested awards and holding lines for Michael Bell

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Bell are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−37Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,137	$32.86	Jun 9, 2033	$1.0M
10,421	$28.37	Dec 13, 2033	$1.6M
59,534	$28.61	Nov 8, 2034	$8.9M
33,498	$43.10	Mar 12, 2035	$4.5M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Craig Eagle

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Craig Eagle

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Craig Eagle are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−26Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,861	$28.37	Dec 13, 2033	$4.5M
47,627	$28.61	Nov 8, 2034	$7.1M
24,363	$43.10	Mar 12, 2035	$3.3M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Terilyn Monroe

Chief People Officer

n/a

−124K

n/a

Vesting, gifts, unvested awards and holding lines for Terilyn Monroe

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Terilyn Monroe are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−25Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,916	$20.14	Feb 26, 2034	$1.7M
18,615	$28.61	Nov 8, 2034	$2.8M
24,363	$43.10	Mar 12, 2035	$3.3M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Kumud Kalia

Chief Information Officer

n/a

−56K

n/a

Vesting, gifts, unvested awards and holding lines for Kumud Kalia

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kumud Kalia are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−28Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,670	$74.00	Apr 20, 2030	$2.9M
34,305	$47.20	Nov 6, 2032	$4.5M
6,414	$32.86	Jun 9, 2033	$928K
9,410	$28.37	Dec 13, 2033	$1.4M
25,721	$28.61	Nov 8, 2034	$3.8M
24,363	$43.10	Mar 12, 2035	$3.3M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Vijaya Gadde

Director

n/a

Vesting, gifts, unvested awards and holding lines for Vijaya Gadde

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Vijaya Gadde are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,703	$31.84	Jun 12, 2034	$1.6M
6,833	$50.57	Jun 18, 2035	$867K

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Steve Krognes

Director

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Steve Krognes

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Steve Krognes are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,703	$31.84	Jun 12, 2034	$1.6M
6,833	$50.57	Jun 18, 2035	$867K

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Myrtle Potter

Director

n/a

−1.6K

n/a

Vesting, gifts, unvested awards and holding lines for Myrtle Potter

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Myrtle Potter are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,703	$31.84	Jun 12, 2034	$1.6M
6,833	$50.57	Jun 18, 2035	$867K

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Meghan Joyce

Director

n/a

−10K

n/a

Vesting, gifts, unvested awards and holding lines for Meghan Joyce

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Meghan Joyce are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,703	$31.84	Jun 12, 2034	$1.6M
6,833	$50.57	Jun 18, 2035	$867K
7,908	$38.42	Jun 14, 2032	$1.1M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Ian Clark

Director

n/a

−50K

n/a

Vesting, gifts, unvested awards and holding lines for Ian Clark

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ian Clark are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Musa Tariq

Director

n/a

−3.3K

n/a

Vesting, gifts, unvested awards and holding lines for Musa Tariq

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Musa Tariq are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,703	$31.84	Jun 12, 2034	$1.6M
6,833	$50.57	Jun 18, 2035	$867K

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Medina Hidalgo

Director

n/a

−8K

n/a

Vesting, gifts, unvested awards and holding lines for Medina Hidalgo

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Medina Hidalgo are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,079	$32.55	Jul 17, 2034	$1.8M
6,833	$50.57	Jun 18, 2035	$867K

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Roberto Mignone

Director

n/a

Vesting, gifts, unvested awards and holding lines for Roberto Mignone

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Roberto Mignone are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,535	$28.61	Nov 8, 2034	$2.9M
6,833	$50.57	Jun 18, 2035	$867K

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Alex Azar II

Director

n/a

−826

n/a

Vesting, gifts, unvested awards and holding lines for Alex Azar II

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alex Azar II are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,532	$54.90	Sep 12, 2035	$1.3M

Estimate: options held × ($177.48 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Holdings and share of stake for Guardant Health, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$168M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $168M across 1,359,415 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $81.1M · 48%

52%

The lighter segment is sales with no plan disclosed in the filing ($86.4M), including tax-related sales outside a plan.

No plan disclosed · $86.4M

Sales with no 10b5-1 plan and no tax reference in the filing. $22.0M of it is Helmy Eltoukhy. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Helmy Eltoukhy, Dec 15, 2025

Taxes

420,489 shares ($49.1M) were withheld by the company for taxes, which isn't a market sale.

Purchases · 1 buyer (1 trade)

1 officer or director bought shares in this period, in 1 trade(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 31 purchase trades.

Charitable gifts · 3K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
AmirAli Talasaz Co-Chief Executive Officer, Director	620K	$77.9M	87%	46%	Dec 8, 2025 to Jun 29, 2026
Helmy Eltoukhy Co-Chief Executive Officer, Director	191K	$22.0M	0%	13%	Dec 15, 2025 to Jun 5, 2026
Chris Freeman Chief Commercial Officer	119K	$16.9M	0%	10%	Dec 5, 2025 to Aug 10, 2026
Terilyn Monroe Chief People Officer	124K	$15.9M	52%	10%	Dec 1, 2025 to Aug 12, 2026
Michael Bell Chief Financial Officer	85K	$8.8M	0%	5%	Dec 5, 2025 to Jun 5, 2026
Ian Clark Director	50K	$6.1M	0%	4%	Dec 5, 2025 to Aug 4, 2026
Kumud Kalia Chief Information Officer	56K	$5.9M	0%	4%	Dec 8, 2025 to Sep 11, 2026
Darya Chudova Chief Technology Officer	36K	$4.4M	0%	3%	Dec 8, 2025 to Sep 15, 2026
John Saia Chief Legal Officer	39K	$4.2M	80%	3%	Nov 7, 2025 to May 27, 2026
Steve Krognes Director	16K	$2.4M	0%	1%	Jun 4, 2026 to Sep 16, 2026
Meghan Joyce Director	10K	$1.3M	100%	0.8%	Jun 3, 2026 to Jun 3, 2026
Medina Hidalgo Director	8K	$936K	0%	0.6%	Nov 7, 2025 to Aug 5, 2026
Musa Tariq Director	3.3K	$411K	100%	0.2%	Oct 17, 2025 to Sep 16, 2026
Myrtle Potter Director	1.6K	$206K	100%	0.1%	Oct 17, 2025 to Jun 22, 2026
Alex Azar II Director	826	$145K	100%	0.1%	Sep 16, 2026 to Sep 16, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$10K	$10K	$0	$0
Nov 2025	$1.0M	$11K	$0	$1.0M
Dec 2025	$43.7M	$5.9M	$0	$37.8M
Jan 2026	$2.1M	$2.1M	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$4.2M	$31K	$0	$4.2M
Apr 2026	$365K	$365K	$0	$0
May 2026	$35.4M	$31.5M	$0	$3.9M
Jun 2026	$56.4M	$41.1M	$0	$15.4M
Jul 2026	$19K	$19K	$0	$0
Aug 2026	$21.0M	$18K	$0	$21.0M
Sep 2026	$3.3M	$165K	$0	$3.2M
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 1.8x the 5-year average. 15 insiders sold; the average is 4 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	1.36M	15	$168M
Oct 13, 2025 1 year earlier	690K	8	$36.9M
Oct 13, 2024 2 years earlier	6.1K	2	$160K
Oct 14, 2023 3 years earlier	15K	2	$546K
Oct 14, 2022 4 years earlier	36K	3	$2.7M
Oct 14, 2021 5 years earlier	3.07M	5	$481M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty18 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Guardant Health, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology866 filings on record, 170 filed in the 12-month period, and how we read them

All 866 Forms 3, 4 and 5 on record for Guardant Health, Inc. (SEC CIK 1576280), filed from Oct 3, 2018 to Oct 2, 2026; 170 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (18)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Amelia Merrill	Mar 4, 2024	27,475 shares, last reported balance as of Mar 1, 2024
Ines Dahne-Steuber	Aug 8, 2023	1,000 shares, last reported balance as of May 3, 2023
Samir Kaul	Jun 16, 2023	16,347 shares, last reported balance as of Jun 14, 2023
Stanley Meresman	Jun 17, 2022	5,873 shares, last reported balance as of Jun 15, 2022
Bahija Jallal	Jun 17, 2022	7,408 shares, last reported balance as of Jun 15, 2022
SOFTBANK VISION FUND (AIV M1) L.P.	Oct 13, 2020	21,075,920 shares, last reported balance as of Oct 9, 2020
Derek Bertocci	Sep 3, 2020	6,373 shares, last reported balance as of Sep 1, 2020
Dipchand Nishar	May 20, 2020	2,982 shares, last reported balance as of May 18, 2020
Michael Wiley	Apr 30, 2020	151,171 shares, last reported balance as of Apr 29, 2020
Richard Lanman	Nov 5, 2019	82,015 shares, last reported balance as of Nov 1, 2019
Aaref Hilaly	Sep 3, 2019	50,421 shares, last reported balance as of Aug 29, 2019
ORBIMED ADVISORS LLC	Oct 11, 2018	8,972 shares, last reported balance as of Oct 9, 2018
Lightspeed Ultimate General Partner X, Ltd.	Oct 11, 2018	3,827,019 shares, last reported balance as of Oct 9, 2018
TLS Beta Pte. Ltd.	Oct 11, 2018	596,012 shares, last reported balance as of Oct 9, 2018
Khosla Ventures IV, L.P.	Oct 11, 2018	44,864 shares, last reported balance as of Oct 9, 2018
SC US (TTGP), LTD.	Oct 11, 2018	74,028 shares, last reported balance as of Oct 9, 2018
SoftBank Group Capital Ltd	Oct 11, 2018	2,033,990 shares, last reported balance as of Oct 9, 2018
Leena Das-Young	Oct 3, 2018	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Guardant Health, Inc. insiders sold $168M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Guardant Health, Inc. CEO selling stock?

Why are Guardant Health, Inc. insiders selling?

Are any Guardant Health, Inc. insiders buying?

The evidence

No plan disclosed · $86.4M

Taxes

Purchases · 1 buyer (1 trade)

Charitable gifts · 3K shares

Sales by month